Targeting metabolic dysregulation of T cells in kidney cancer.
Katy Beckermann(Vanderbilt University Medical Center), Jeffrey C. Rathmell(University of Chicago), Benjamin G. Vincent(University of North Carolina at Chapel Hill), Sierra Barone(Vanderbilt University), Jonathan M. Irish(Vanderbilt University), Kirsten Young, Rachel A. Hongo, Caroline E. Roe(Vanderbilt University), Christof C. Smith(Dana-Farber Cancer Institute), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Xiang Ye(Qilu Hospital of Shandong University), Diana Contreras
Cited by 14
Related Papers
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
|The Journal of Immunology|2011|2k
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
|Cancer Cell|2014|867
Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways
|The Journal of Immunology|2008|836
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
|Cell Reports|2018|818
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
|Cancer Cell|2017|791